Life
Briefing: A setback for Roche’s breast cancer drug
Strategic angle: Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news
editorial-staff
1 min read
Updated about 1 month ago
Summary
- Summary pending editorial review.
Key Facts
- Key facts pending editorial review.